69 hasil
Menampilkan 1–20 · 0,21 detik · RSS
Hepatic Oncology
Scopus
ISSN 2045-0931 · Taylor & Francis · 69 artikel di indeks
-
Artikel Jurnal
Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality and arises predominantly in cirrhotic livers, making prognosis and treatment response highly dependent on hepatic reserve and comorbidity. With multiple first-line immunotherapy and anti-VEGF based regimens, real-world…
-
Artikel Jurnal
Advances in liver transplantation for hepatic malignancies
Transplant Oncology is an evolving field. While liver transplantation was once contraindicated in patients with cancer, the safety and survival benefit of utilizing transplantation as a curative-intent treatment for primary and metastatic hepatic malignancies has been demonstrated. Currently, liver…
-
Artikel Jurnal
Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study
Aims To evaluate the clinical and pathological characteristics of hepatocellular carcinoma (HCC) diagnosed at a tertiary care center in Saudi Arabia over a 10-year period.Materials and Methods This retrospective observational study included 44 patients diagnosed with HCC between January 2014 and…
-
Artikel Jurnal
Racial and ethnic survival disparities in primary liver cancer in the United States: a National Cancer Database propensity score-matched study
Introduction Primary liver cancer is a leading cause of cancer mortality worldwide. We evaluated whether racial and ethnic survival disparities among US patients with primary liver cancer persist after adjustment for clinical, treatment, socioeconomic, and access-related factors.Methods We…
-
Artikel Jurnal
RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells
Introduction Hepatocellular carcinoma (HCC) remains difficult to treat, highlighting the need for new therapeutic strategies. RTA-408 (omaveloxolone), a synthetic oleanane triterpenoid and NRF2 pathway modulator, has reported anticancer activity, but its mechanisms in HCC are not fully…
-
Artikel Jurnal
Management of hepatocellular carcinoma prior to liver transplantation: latest developments
Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts…
-
Artikel Jurnal
Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy
Hepatocellular carcinoma (HCC) remains a health concern characterized by heterogeneity and high mortality. Surgical resection, radiofrequency ablation, trans-arterial chemoembolization, and liver transplantation offer potentially curative treatments for early-stage disease, but recurrence remains…
-
Artikel Jurnal
Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update
Aims Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.Methods In this prospective trial…
-
Artikel Jurnal
HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies
This was a narrative review of select studies published through September of 2024. We review the shift toward multi-dimensional scores such as HCC early detection screening (HES), GALAD, ASAP, and mt-HBT represents a significant advancement in biomarker research for hepatocellular carcinoma (HCC)…
-
Artikel Jurnal
Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation
Aim Real-world outcomes in early-stage hepatocellular carcinoma (eHCC) are not well characterized. We aimed to evaluate treatment patterns and long-term outcomes in patients with eHCC treated with resection or ablation in the United States.Materials and methods We conducted a retrospective study…
-
Artikel Jurnal
Two-way increased-risk associations between hepatobiliary cancers and other malignancies: a population-based study
Aim Our aim was to examine two-way increased-risk associations between hepatobiliary cancers and malignancies that develop before/after them.Patients and methods Data of USA from Surveillance, Epidemiology, and End Results (SEER), 17 registries (2000–2021) were analyzed using different statistical…
-
Artikel Jurnal
Clinical management of liver cancer patients with immune checkpoint inhibitors treatment
The treatment paradigm of hepatocellular carcinoma (HCC) has evolved with the emergence of immune checkpoint inhibitors (ICIs). Two ICI-based regimens have gained regulatory approval worldwide in unresectable HCC as first line treatment based on the IMBrave150 and HIMALAYA trial. Other regimens…
-
Artikel Jurnal
Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma
Aim The present study aimed to explore the patient experience in advanced and/or metastatic hepatocellular carcinoma (HCC).Materials & methods A multi-phase research design was followed that included a targeted literature review (TLR), interviews with clinicians, and interviews with patients…
-
Artikel Jurnal
Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape
Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. Molecular profiling of biliary tract cancers (BTCs) has changed the treatment landscape positively by prolonging survival in an aggressively fatal malignancy in its advanced stages…
-
Artikel Jurnal
Comparison of long-term clinical outcomes between radiofrequency ablation and hepatic resection in patients with small (≤2 cm) hepatocellular carcinoma
Aim: The present study aimed to compare the long-term survival outcomes of hepatic resection (HR) and radiofrequency ablation (RFA) in patients with single small (≤2 cm) hepatocellular carcinoma (HCC).Materials & methods: This retrospective study enrolled patients with a single small HCC measuring…
-
Artikel Jurnal
Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases
Aim: To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis.Materials & methods: Survival outcome was compared between groups with immunotherapy and groups without…
-
Artikel Jurnal
APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage
Aim: The aim of this study was to assess the utility of weighted amide proton transfer (APTw) MRI in three different rodent models of hepatocellular carcinoma (HCC).Methods: APTw MRI was evaluated in models of diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft and human HepG2…
-
Artikel Jurnal
Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting
Aim: Many pivotal trials in advanced hepatocellular carcinoma (HCC) require participants to have Child-Pugh A disease. However, many patients in real-world practice are Child-Pugh B or C. This study examined treatment patterns and clinical outcomes in patients with advanced HCC treated with…
-
Artikel Jurnal
The predictive value of liver tests for the presence of liver metastases
Aim: To analyze the predictive value of biochemical liver tests in patients with malignant melanoma, breast, colorectal or lung cancers at the time of diagnosis of liver metastases. Methods: A retrospective review of patients with the above-mentioned solid tumors at MedStar Georgetown University…
-
Artikel Jurnal
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
Aim: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma. Patients & methods: Retrospective…